For metastatic NSCLC patients who already harbored mutations prior to treatment, such as BRAF,317 cMET and KRASG12C399 and HER-2 mutations,400 treatment for their respective targets can be provided. This evidence concerns the gene BRAF and non-small cell lung carcinoma.